Sign in to view content

Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results

Jeffrey S. Heier, MD

Video
Published 2019

Jeffrey S. Heier, MD

AMD Non-neovascular Symposium

Related

Early Fluid-Free Status & Long-Term BCVA Outcomes With Anti-VEGF Treatment in nAMD: Post Hoc Analysis of Pooled Data From HAWK & HARRIER Studies
Chirag D. Jhaveri, MD, FASRS
On Demand Cases, Courses, and Papers
2020
EVEREST II Study: Evaluation of Indocyanine Green Angiographic Features in Symptomatic Macular Polypoidal Choroidal Vasculopathy Over 24 Months
Colin S Tan, MBBS, MMed (Ophth), FRCSEd (Ophth)
Annual Meeting Talks
2019
96-Week Visual and Expanded Anatomical Outcomes of Brolucizumab Versus Aflibercept in Patients With nAMD: Results From HAWK and HARRIER
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2019

Category: AMD-Non-Neovascular

See more